Alemtuzumab (Campath-1H) combined with XXXX in intestinal and multivisceral transplantation.

@entity1 @entity2803 @entity3446 @entity134 @entity364 @entity1140 @entity230 @entity1292
BACKGROUND: We combined alemtuzumab (Campath-1H, Berlex Laboratories, Montville, NJ) and @entity1140 (Tac) immunosuppression for intestinal and multivisceral transplantation. MATERIALS AND METHODS: A total of 21 adult @entity1 received 24 grafts: 14 intestinal, nine multivisceral, and one liver-intestinal graft. Alemtuzumab was administered perioperatively in four doses with low-dose Tac (levels 10-15 ng/dL) and no maintenance @entity230 . Tac was substituted with @entity3446 in case of Tac-related complications. Suspected or mild rejections were treated with @entity230 . Moderate rejections were treated with @entity230 or OKT3. Severe rejections were treated with OKT3. RESULTS: Of the 16 @entity1 that were followed up for an average of 9 months, 12 are alive with functioning grafts. Two @entity1 experienced severe rejection, three experienced moderate rejection episodes, and seven experienced mild acute rejection episodes. Four @entity1 never developed acute rejection. Infectious complications included a @entity2803 and four @entity364 (related to central venous access). CONCLUSIONS: The combination of alemtuzumab and Tac therapy without @entity134 use seems to efficiently prevent acute rejection in a significant number of @entity1 without causing frequent @entity1292 .
